As we welcome 2026, we step into a new year filled with renewed possibility.
The global landscape continues to shift at remarkable speed: technologies evolve, markets realign, and societies face challenges that demand bold, collaborative solutions.

Amid this momentum, one truth stands out: innovation has never been more essential, nor more global. Cross‑border expansion is no longer just a pathway for business growth but also a means to ensure progress is shared, communities are strengthened, and new systems take shape for a better future.

In 2026, we reaffirm our mission to help innovators navigate cross-border expansion complexity with clarity, agility, and purpose. Whether it’s crafting and executing culturally resonant market strategies, forging commercial engagements, or building strategic partnerships, we remain dedicated to enabling companies to spread their innovative products, solutions or services internationally and create net‑positive impact wherever they operate.

Together, let’s build a brighter and more inclusive future.
Happy New Year 2026.
​
Bruno & Brian
encognize G.K. Cross-Border Innovation Partners

As 2025 draws to a close, we’re taking a moment to reflect on how far we’ve advanced the frontier of cross‑border innovation together.

Even amid a global VUCA landscape, APAC continued to stand out as a compelling destination for innovators pursuing regional or global growth. This year, we had the privilege of supporting 35 pioneering companies from 8 European and Asian countries, through both government‑backed programs and tailored fractional support, as they navigated their expansion journeys. Japan and ASEAN once again emerged as top destinations for ambitious founders looking to scale.

Two‑thirds of the companies we engaged with this year were focused on building an initial understanding of their target markets. We supported them through strategic market entry preparation, combining contextual and industry‑specific insights delivery, GTM assumption and hypothesis development, and organization‑level stakeholder mapping, with on‑the‑ground exploration and validation through targeted meetings.

Another 11 companies had already pre‑validated their target markets and partnered with us to de‑risk and accelerate their entry. Through deeper, higher‑intensity engagements with several of them, we helped deliver tangible outcomes within 3 to 6 months, ranging from identifying business, technological, and commercial partners to finding validation projects.

We extend our sincere thanks to the many startups, scale‑ups, corporations, and government organizations that entrusted us throughout 2025 to support their international expansion and innovation journeys.

We look forward to continuing to push the boundaries of global innovation together in 2026.

Bruno & Brian
encognize G.K. Cross-Border Innovation Partners

As part of our XBORDR service line, our encognize Cross-Border Expansion Validation Partners collaborated throughout  with the Global Incubator Network (GIN) Austria and the Austrian Research Promotion Agency FFG during Q3 2025 to support strategic preparation for cohorts of innovative Life Science, BioTech and MedTech companies targeting market expansion into Japan and Singapore.

These healthcare / medical sector innovation-focused expansion support activities are fully embedded within our X.HEALTH initiative:
「Building the Future of Healthcare in Japan, Singapore/SEA and South Korea」,
an initiative that encompasses Expansion Strategic Preparation, Expansion De-Risking & Market Validation and Expansion Strategy Field Execution support delivered through group missions or bespoke team augmentation services with our medical experts network business partner.

As of October 2025, we have supported more than 30 startups & scaleups from 10 different countries with innovation spanning the entire Healthcare and Medical Ecosystem (MedTech, BioTech & Life Sciences, HealthTech & Digital Health) in their expansion journeys.

Examples of supported innovation to date include:

• AI SaMD for specific cancer types detection
• Algae-based biomaterial development
• AI Drug Discovery Platform
• AI-based sleep analysis
• Biofeedback device for amputees
• Mental health digital app
• Organoid-based regenerative medicine platform
• Digital early childhood developmental delay screening and intervention
• Bedsore detection device
• ...

Sample of outcomes realized for the companies we have supported (for different types of engagements and maturities) include:

• medical device early adopter identification and qualification
• joint validation project qualification with medical organization
• finding and confirming distributor for musculoskeletal disease prevention solution
• securing government-led ASEAN cross-country collaboration engagement
• regulatory / reimbursement strategy hypothesis and related execution pathways
• ...